Elizabeth D. Tate

Orlando Immunology Center — United States

Medicine · Health Sciences

24h-index1.6kcitations54works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Autoimmune Neurological Disorders and Treatments(36), Glycogen Storage Diseases and Myoclonus(28), Genetics and Neurodevelopmental Disorders(16), Neuroblastoma Research and Treatments(7), Epilepsy research and treatment(5)

Publications53 total

Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome
Pediatric Neurology·2018· 14 cited
Multifactorial analysis of opsoclonus‐myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children
Pediatric Blood & Cancer·2018· 31 citedOpen Access
Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS
Journal of Neuroimmunology·2018· 11 citedOpen Access
Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study
European Journal of Paediatric Neurology·2018· 8 cited
Intensive Combination Immunotherapy and Neuroinflammation Resolution in a Child With Anti-PCA-1 (Yo) Paraneoplastic Syndrome and 2 Malignancies
Child Neurology Open·2018· 2 citedOpen Access
Rituximab, IVIg, and Tetracosactide (ACTH1–24) Combination Immunotherapy (“RITE-CI”) for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations
Neuropediatrics·2017· 9 cited
Corrigendum to “Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome” [Pediatric Neurology 73 (2017) 48–56]
Pediatric Neurology·2017· 2 citedOpen Access
Response to Sharawat and Suther
Pediatric Neurology·2017
Microglial/macrophage markers CHI3L1, sCD14, and sCD163 in CSF and serum of pediatric inflammatory and non-inflammatory neurological disorders: A case-control study and reference ranges
Journal of the Neurological Sciences·2017· 19 cited
Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome
Pediatric Neurology·2017· 34 cited
Case-control, exploratory study of cerebrospinal fluid chemokines/cytokines and lymphocyte subsets in childhood Tourette syndrome with positive streptococcal markers
Cytokine·2017· 16 cited
Corrigendum to “Chemokine/cytokine profiling after rituximab: Reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS” [Cytokine 53 (2011) 384–389]
Cytokine·2017
Opsoclonus Myoclonus Syndrome
Elsevier eBooks·2017· 3 cited
Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome
Brain and Development·2016· 51 cited
PHARMACODYNAMICS OF IMMUNOTHERAPY FOR OPSOCLONUS-MYOCLONUS SYNDROME: IMPACT ON CYTOKINES/CHEMOKINES
13th International Child Neurology Congress (ICNC2014)·2014
Clinical and Demographic Features of 389 Children with OMS: an International Cohort
13th International Child Neurology Congress (ICNC2014)·2014· 4 cited
CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders
Journal of Neuroimmunology·2013· 32 cited
Paraneoplastic movement disorders in childhood
Movement Disorders·2013· 1 cited
200
Cytokine·2013
CCR7 signaling in pediatric opsoclonus–myoclonus: Upregulated serum CCL21 expression is steroid-responsive
Cytokine·2013· 13 cited
page 1 of 3Next →

Frequent Co-authors

Michael R. Pranzatelli(47), Nathan R. McGee(14), Anna L. Travelstead(12), Jerry A. Colliver(9), Tyler Allison(7), Steven J. Verhulst(6), Richard M. Ransohoff(4), Suja A. Joseph(3), David Neal Franz(2), Howard Kelfer(2), Yasmin Khakoo(2), Jennifer A. Swan(2), W. Graf(2), Wendy G. Mitchell(2), Jayne Ness(2), Michael R. Pranzate(1), Steven J. Verhu(1), Jerry L. Barbosa(1), Robert A. Bergamini(1), Lucy Civitello(1)